Search results

A “super” receptor that helps kill HIV infected cells identified.

The Chair of ANSTO, The Hon Dr Annabelle Bennett, AC SC, announced today that Mr Shaun Jenkinson has been reappointed as the Chief Executive Officer of ANSTO.

At ANSTO we understand that diverse teams produce better outcomes – and we value the merit that a diverse perspective can bring to the quality and outcomes of our work, and the way we get the job done.

ANSTO providing support to emergency services, closed to non-essential staff.

ANSTO is celebrating the official opening of HIFAR, Australia’s first nuclear reactor, sixty-five years ago.

Just under 250 schools in Australia and one school in Malaysia will participate in a series of science-based competitions during to coincide with National Science Week in 2024.

View the upcoming proposal deadlines for access to ANSTO’s Research Portal. The User Office provides support for research proposals and enables you to leverage our world-class research infrastructure and facilities.

ANSTO today welcomed a significant Federal Government funding allocation to further safeguard the production of life-saving nuclear medicines in Australia.

The independent nuclear regulator, ARPANSA, is currently accepting submissions about ANSTO’s planned $59.8 million Intermediate Level Solid Waste Storage Facility.

The Chair of ANSTO, The Hon Dr Annabelle Bennett, AC SC, announced today that Mr Shaun Jenkinson has been appointed Chief Executive Officer of ANSTO following a global search for the position.

Stage 1 of the Stawell Underground Physics Laboratory was officially opened today. It will be home to multi-disciplinary scientists from five research partners who help us understand dark matter.

ANSTO facilitating coordinated effort to find the nexus that leads to chronic kidney disease of unknown origin

ANSTO has hosted an event to launch a new Dharawal language learning resource for primary students at the nandin innovation centre.

This afternoon, the Chair of ANSTO, Dr Annabelle Bennett, wrote to all staff to let them know that CEO Dr Adi Paterson has decided to resign. She said the Board is deeply appreciative of the contributions Adi has made, including to the health, research and academic outputs of ANSTO during his tenure. Mr Shaun Jenkinson will continue as Acting CEO, while the Board undertakes a global search for a permanent CEO.

ANSTO has been licensed as the Australian manufacturing partner of an innovative, non-invasive treatment for non-melanoma skin cancer (NMSC).

Best and brightest recognised in 2017 research awards